BRAF and colorectal cancer: CDK1 inhibition by dinaciclib overcomes apoptotic resistance in BRAF‐Mutant Human Colorectal Cancer.26 Combined with our research and other studies, it has been shown that Dinaciclib can exert therapeutic effects through different mechanisms in different diseases.